PMBCT-01 is under clinical development by PeproMene Bio and currently in Phase I for Primary Mediastinal B-Cell Lymphoma. According to GlobalData, Phase I drugs for Primary Mediastinal B-Cell Lymphoma have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PMBCT-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

PMBCT-01 overview

PMBCT-01 is under development for the treatment of B-cell non-Hodgkin lymphoma including Burkitt lymphoma, mantle cell lymphoma and relapsed or refractory B-cell acute lymphoblastic lymphoma (r/r B-ALL) including primary mediastinal large B-cell lymphoma (PMBCL), transformed follicular lymphoma (tFL), and transformed marginal zone lymphoma (tMZL). The therapeutic candidate consists of lentiviral vector comprises of T-cells expressing chimeric antigen receptor (CAR) engineered to express an anti-BAFFR antibody derived single chain fragment (scFv). It acts by targeting TNFRSF13C expressing cells. It is administered through parenteral route. 

PeproMene Bio overview

PeproMene Bio., is a developer of novel immune-oncology therapies. The company is headquartered in United States.

For a complete picture of PMBCT-01’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.